{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:32Z","timestamp":1790188232663,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High-Level Hospital Clinical Research Funding (Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital\uff09","award":["2022CX04"],"award-info":[{"award-number":["2022CX04"]}]},{"name":"National High-Level Hospital Clinical Research Funding (Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital\uff09","award":["2022CX14"],"award-info":[{"award-number":["2022CX14"]}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2022-2Z-40712"],"award-info":[{"award-number":["2022-2Z-40712"]}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["2016YFC0904900"],"award-info":[{"award-number":["2016YFC0904900"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872940"],"award-info":[{"award-number":["81872940"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973395"],"award-info":[{"award-number":["81973395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073935"],"award-info":[{"award-number":["82073935"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40262-022-01208-0","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:03:59Z","timestamp":1675440239000},"page":"435-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated Pharmacokinetics\/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome"],"prefix":"10.1007","volume":"62","author":[{"given":"Zhiyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"issue":"7","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2165\/11206850-000000000-00000","volume":"71","author":"ED Deeks","year":"2011","unstructured":"Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs. 2011;71(7):909\u201333.","journal-title":"Drugs"},{"issue":"15","key":"1208_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jacc.2014.01.038","volume":"63","author":"KW Mahaffey","year":"2014","unstructured":"Mahaffey KW, Held C, Wojdyla DM, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014;63(15):1493\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"1208_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002490","volume":"4","author":"P Andell","year":"2015","unstructured":"Andell P, James SK, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015;4(10): e002490.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"1208_CR5","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1208_CR6","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 CC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-155.","journal-title":"Circulation"},{"issue":"37","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1093\/eurheartj\/ehaa624","volume":"41","author":"J-P Collet","year":"2020","unstructured":"Collet J-P, Thiele H. The \u2018Ten Commandments\u2019 for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J. 2020;41(37):3495\u20137.","journal-title":"Eur Heart J"},{"key":"1208_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","volume":"32","author":"LB Sheiner","year":"1992","unstructured":"Sheiner LB, Ludden TM. Population pharmacokinetics\/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185\u2013209.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"1208_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5414\/CP202549","volume":"54","author":"J Li","year":"2016","unstructured":"Li J, Tang W, Storey RF, Husted S, Teng R. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 2016;54(9):666\u201374.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1208_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5414\/CP202748","volume":"55","author":"D R\u00f6shammar","year":"2017","unstructured":"R\u00f6shammar D, Bergstrand M, Andersson T, Storey RF, Hamr\u00e9n B. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int J Clin Pharmacol Ther. 2017;55(5):416\u201324.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.xphs.2019.03.028","volume":"108","author":"M Zhang","year":"2019","unstructured":"Zhang M, You X, Ke M, Jiao Z, Wu H, Huang P, Lin C. Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics. J Pharm Sci. 2019;108(8):2781\u201390.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1208_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00228-018-2427-3","volume":"74","author":"S Liu","year":"2018","unstructured":"Liu S, Xue L, Shi X, Sun Z, Zhu Z, Zhang X, Tian X. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Eur J Clin Pharmacol. 2018;74(6):745\u201354.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-019-00758-0","volume":"58","author":"C Amilon","year":"2019","unstructured":"Amilon C, Niazi M, Berggren A, \u00c5strand M, Hamr\u00e9n B. Population pharmacokinetics\/pharmacodynamics of ticagrelor in children with sickle cell disease. Clin Pharmacokinet. 2019;58(10):1295\u2013307.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bcp.13812","volume":"85","author":"M \u00c5strand","year":"2019","unstructured":"\u00c5strand M, Amilon C, R\u00f6shammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamr\u00e9n B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol. 2019;85(2):413\u201321.","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"key":"1208_CR16","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","volume":"878","author":"H Sill\u00e9n","year":"2010","unstructured":"Sill\u00e9n H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299\u2013306.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"1208_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-022-01154-6","volume":"42","author":"Q Xiang","year":"2022","unstructured":"Xiang Q, Liu Z, Mu G, Xie Q, Zhang H, Zhou S, Wang Z, Guo N, Huang J, Jiang J, Li J, Yang G, Cui Y. Effect of genetic polymorphism including NUP153 and SVEP1 on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy Chinese subjects. Clin Drug Investig. 2022;42(5):447\u201358.","journal-title":"Clin Drug Investig"},{"key":"1208_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharm Syst Pharmacol. 2013;2: e50.","journal-title":"CPT Pharm Syst Pharmacol"},{"issue":"6","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387\u2013404.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"1208_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00228-018-2427-3","volume":"74","author":"S Liu","year":"2018","unstructured":"Liu S, Xue L, Shi X, et al. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Eur J Clin Pharmacol. 2018;74(4):745\u201354.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1208_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5414\/CP202748","volume":"55","author":"D Rshammar","year":"2017","unstructured":"Rshammar D, Bergstrand M, Andersson T, et al. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int J Clin Pharmacol Ther. 2017;55(5):416.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016;67(10):1145\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1208_CR23","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261\u201373.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"1208_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.numecd.2015.12.015","volume":"26","author":"L Barbieri","year":"2016","unstructured":"Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, et al. Novara Atherosclerosis Study Group (NAS). Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutr Metab Cardiovasc Dis. 2016;26(4):352\u20138.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"1208_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.thromres.2016.10.013","volume":"149","author":"D Venetsanos","year":"2017","unstructured":"Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res. 2017;149:88\u201394.","journal-title":"Thromb Res"},{"issue":"10","key":"1208_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2015","unstructured":"Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2015;34(10):1077\u201390.","journal-title":"Pharmacotherapy"},{"key":"1208_CR27","first-page":"29","volume":"15","author":"D Yuan","year":"2022","unstructured":"Yuan D, Shi X, Gao L, Wan G, Zhang H, Yang Y, et al. Identification of potential biological factors affecting the treatment of ticagrelor after percutaneous coronary intervention in the Chinese population. Pharmgenomics Pers Med. 2022;15:29\u201343.","journal-title":"Pharmgenomics Pers Med."},{"issue":"32","key":"1208_CR28","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.2174\/0929867328666201231124715","volume":"28","author":"V Conti","year":"2021","unstructured":"Conti V, Corbi G, Manzo V, Sellitto C, Iannello F, Esposito S, De Bellis E, Iannaccone T, Filippelli A. The role of pharmacogenetics in antithrombotic therapy management: new achievements and barriers yet to overcome. Curr Med Chem. 2021;28(32):6675\u2013703.","journal-title":"Curr Med Chem"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01208-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:44:26Z","timestamp":1679895866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01208-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01208-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"29 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by grants from the National High-Level Hospital Clinical Research Funding (Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital, 2022CX04 and 2022CX14), Capital\u2019s Funds for Health Improvement and Research (2022-2Z-40712), the National Key R&D Program of China (2016YFC0904900), and National Natural Science Foundation of China (81872940, 81973395 and 82073935).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zhiyan Liu, Yaou Liu, Guangyan Mu, Hanxu Zhang, Shuang Zhou, Zhe Wang, Qiufen Xie, Zining Wang, Ninghong Guo, Jie Huang, Liping Guo, Yan Huang, Jian Li, Guoping Yang, Dongdong Yuan, Hongtao Song, Jie Jiang, Qian Xiang, and Yimin Cui declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interest"}},{"value":"This study was approved by an independent ethics committee and the Institutional Review Board of Peking University First Hospital and all the participating subcentral hospitals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All involved subjects were briefed on the study and provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All data related to the study are shown in the article and supplementary materials. For access to other relevant data, contact the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"YMC and QX designed the research; ZYL, GYM, HXZ, NHG, JH, JJ, JL, DDY, YH, HTS and GPY performed experiments and collected data; YOL, SZ, ZW, QFX, and ZNW analyzed the data; ZYL and YOL wrote the manuscript. All authors have read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}